Table 1 Patient demographics, vaccine history, and symptoms
From: Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections
Sample | Sex | Age | Height (cm) | Weight (kg) | Vaccine received | First dose | Second dose | Symptoms | Comorbidities† | N1 qPCR Ct | Day of positive test | Clinical outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient 0a | Male | 67–69 | 177.8 | 81.6 | Covaxin BBV152 | 2021-03-02 | 2021-03-31 | Fever, cough, body aches, fatigue, loss of taste and/or smell, Shortness of breath at rest, Shortness of breath with activity | None | 29 | Day 4 | Deceased |
Patient 0b | Female | 65–70 | 152.4 | 53 | Covaxin BBV152 | 2021-03-02 | 2021-03-30 | Fever, cough, body aches, fatigue, loss of taste and/or smell, Shortness of breath at rest, Shortness of breath with activity | Diabetes | 27 | Day 4 | Recovered |
Patient 1 | Male | 60–66 | 172 | 68 | Pfizer BNT162b2 | 2021-12-30 | 2021-01-20 | Cough, fatigue | None | 17 | Day 4 | Recovered |
Patient 2 | Male | 59–64 | 170.1 | 77 | Pfizer BNT162b2 | 2021-01-07 | 2021-01-28 | Fever, cough, fatigue | Hypertension | 24 | Day 5 | Recovered |
Patient 3 | Female | 51–56 | 155 | 63.5 | Moderna mRNA-1273 | 2020-12-30 | 2021-01-26 | Fever, cough, body aches, fatigue, loss of taste and/or smell | Overweight | 25 | Day 5 | Recovered |
Patient 4 | Female | 51–56 | 162.6 | 88.5 | Moderna mRNA-1273 | 2021-01-04 | 2021-02-01 | Fatigue, loss of taste and/or smell | Overweight | 22 | Day 5 | Recovered |